Polaryx Therapeutics, Inc.
PLYX
$2.27
-$0.19-7.72%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.48M | -8.99M | -8.21M | -7.55M | -7.80M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 741.00K | 4.73M | 4.76M | 4.65M | 5.46M |
| Change in Net Operating Assets | 438.00K | 316.00K | 144.00K | -852.00K | -884.00K |
| Cash from Operations | -5.30M | -3.94M | -3.31M | -3.76M | -3.22M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | 0.00 | 0.00 | -193.00K |
| Issuance of Common Stock | 4.24M | 4.49M | 6.48M | 3.00M | 7.57M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -27.00K | -27.00K | -156.00K | -- | -- |
| Cash from Financing | 4.22M | 4.47M | 6.33M | 3.00M | 7.38M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.08M | 522.00K | 3.01M | -759.00K | 4.16M |